The white, round tablet debossed with AN 627 is an immediate-release oral prescription medication containing Tramadol Hydrochloride (50 mg), a centrally acting synthetic opioid analgesic with dual mechanism properties.
Pill Identification
Attribute – Specification
- Active Ingredient – Tramadol Hydrochloride, USP (50 mg)
- Imprint – AN 627 on one side; plain or scored on the reverse
- Color & Shape – White, round tablet
- Size – Approximately 9 mm
- Manufacturer – Amneal Pharmaceuticals
- Drug Class -l Centrally acting synthetic opioid analgesic / Dual reuptake inhibitor
- Controlled Substance Schedule – DEA Schedule IV (C-IV)
Mechanism of Action
Tramadol achieves analgesia through a distinct, dual-target neurochemical mechanism:
- Weak Opioid Receptor Agonism: Tramadol binds weakly to central mu-opioid receptors. In the liver, it is metabolized by the cytochrome P450 CYP2D6 enzyme into its primary active metabolite, desmethyltramadol (M1), which possesses significantly higher affinity (up to 300 times greater) for opioid receptors than the parent drug. Activation of these receptors hyperpolarizes neurons and blocks ascending nociceptive pain pathways.
- Inhibition of Monoamine Reuptake: Independent of its opioid effects, tramadol acts as a reuptake inhibitor of serotonin (5-HT) and norepinephrine (NE) in the central nervous system. This elevates synaptic monoamine concentrations in the spinal dorsal horn, enhancing descending pain-inhibitory neural pathways.
Indications and Clinical Uses
- Moderate to Moderately Severe Pain: Indicated for the management of acute or chronic moderate-to-moderately-severe pain (such as post-surgical pain, dental trauma, fractures, or osteoarthritis flares) when non-opioid options like NSAIDs or acetaminophen are ineffective, contraindicated, or insufficient.
Dosage and Administration
- Dosing must be individualized and kept at the lowest effective dose for the shortest duration necessary.
- Adult Acute Pain Dosing: Typically 50 mg to 100 mg orally every 4 to 6 hours as needed for pain.
- Maximum Daily Dose: Do not exceed 400 mg per day in adults (or 300 mg per day in elderly patients aged 75 years and older).
- Titration for Chronic Pain: To minimize initial adverse effects (particularly nausea and dizziness), a titration schedule starting at 25 mg/day and increasing in 25–50 mg increments every 3 days is often utilized.
- Severe Renal Impairment : Dosing interval is extended to every 12 hours, with a maximum daily limit of 200 mg.
- Severe Hepatic Impairment (Cirrhosis): Recommended dose is 50 mg every 12 hours.
- Discontinuation: If taken regularly for more than a few days, treatment must be tapered gradually to prevent both opioid withdrawal and antidepressant-like discontinuation symptoms.
Side Effects
Common Adverse Reactions:
- Gastrointestinal: Nausea, vomiting, constipation, dry mouth, dyspepsia
- Central Nervous System: Dizziness, lightheadedness, somnolence/drowsiness, headache, fatigue, tremor
- Autonomic: Hyperhidrosis (excessive sweating), flushing, pruritus
Serious Adverse Reactions:
- Seizure Induction: Tramadol lowers the seizure threshold and can induce seizures even at recommended doses, with elevated risk at high doses or in patients taking other seizure-lowering agents.
- Life-Threatening Respiratory Depression: Severe bradypnea, shallow breathing, or fatal respiratory arrest.
- Serotonin Syndrome: Potentially fatal monoaminergic toxicity characterized by clonus, tremor, hyperreflexia, hyperthermia, and autonomic instability.
- Adrenal Insufficiency & Hypotension: Decreased corticosteroid output or sudden postural blood pressure drops.
Key Drug Interactions
- Serotonergic Medications: Concurrent administration with SSRIs, SNRIs, tricyclic antidepressants, triptans, or St. John’s wort substantially raises the risk of Serotonin Syndrome.
- MAO Inhibitors: Strictly contraindicated with or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risks of hypertensive crisis and fatal serotonin toxicity.
- CYP2D6 & CYP3A4 Modulators:
- CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine, bupropion) reduce conversion to the active M1 metabolite, lowering analgesia while increasing parent drug accumulation and seizure risk.
- CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin) increase tramadol systemic exposure.
- CNS Depressants & Alcohol: Co-ingestion with alcohol, benzodiazepines, barbiturates, or sedatives causes additive CNS depression and exponentially increases the risk of fatal respiratory failure.
Boxed Warnings and Contraindications
- Addiction, Abuse, and Misuse: Tramadol carries risks of addiction, abuse, and misuse leading to overdose and death (Schedule IV controlled substance).
- Life-Threatening Respiratory Depression: Fatal respiratory depression may occur, especially during therapy initiation or dosage escalation.
- Ultra-Rapid CYP2D6 Metabolism: Patients who are CYP2D6 ultra-rapid metabolizers convert tramadol into M1 significantly faster, resulting in unexpectedly high opioid levels and life-threatening respiratory arrest.
- Contraindications:
- Pediatric Restrictions: Strictly contraindicated in all children under 12 years of age, and in adolescents under 18 years following tonsillectomy and/or adenoidectomy.
- Significant respiratory depression or acute/severe bronchial asthma in unmonitored settings.
- Known or suspected gastrointestinal obstruction (including paralytic ileus).
- Concomitant use with or within 14 days of MAOIs.
- Hypersensitivity to tramadol or any tablet excipients.